Compare PNRG & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNRG | CDXS |
|---|---|---|
| Founded | 1973 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Major Chemicals |
| Sector | Energy | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.2M | 256.3M |
| IPO Year | 1995 | 2008 |
| Metric | PNRG | CDXS |
|---|---|---|
| Price | $183.82 | $2.25 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $160.00 | N/A |
| AVG Volume (30 Days) | 54.4K | ★ 872.0K |
| Earning Date | 04-16-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | ★ 1.82 | N/A |
| Revenue | ★ $189,052,000.00 | $138,590,000.00 |
| Revenue This Year | N/A | $7.73 |
| Revenue Next Year | $18.18 | $14.24 |
| P/E Ratio | $102.44 | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $126.40 | $0.96 |
| 52 Week High | $278.90 | $3.87 |
| Indicator | PNRG | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 43.33 |
| Support Level | $160.51 | $1.57 |
| Resistance Level | $187.50 | $2.72 |
| Average True Range (ATR) | 7.87 | 0.16 |
| MACD | 2.93 | -0.03 |
| Stochastic Oscillator | 78.17 | 22.88 |
PrimeEnergy Resources Corp is an independent oil and natural gas company that is engaged in acquiring, developing, and producing oil and natural gas. It owns producing and non-producing properties located in Texas and Oklahoma. The company's business activities include development and exploratory drilling and providing well servicing support operations for many of the onshore oil and gas wells through its subsidiaries. It is also active in the acquisition of producing oil and gas properties through joint ventures with industry partners.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.